Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the biologic activity of EGFR
- Summarize the use of tyrosine kinase inhibitors and monoclonal antibodies in the treatment of EGFR-overexpressing cancers
- Review strategies for improving the efficacy of targeted anti-EGFR agents
Topics covered include:
- Introduction
- EGFR Structure and Normal Biological Function
- How Current Therapeutic Agents Exploit EGFR as a Target
- Small-Molecule Inhibitors of EGFR
- Activity of Anti-EGFR Monoclonal Antibodies
- Identifying Alternate Signaling Pathways That Might Enhance the Response to EGFR-Targeted Therapies
- Optimizing Antibody-Dependent Cellular Cytotoxicity for Enhanced Monoclonal Antibody Activity
- Identifying Ancillary Targets of EGFR for Enhanced Monoclonal Antibody Activity
- Summary